FAQ: Kode Technology and FSL constructs

What is Kode Technology?

Kode Technology is a biosurface engineering platform that adds a new function to the surface of almost any cell, virus or material, living or inert. It works through Function-Spacer-Lipid (FSL) constructs: synthetic, water-dispersible molecules that insert into a membrane or attach onto a surface within minutes.

No genetic change is involved and, in the published method, the modification does not affect the cell's viability or normal function. On living cells the change is temporary, lasting days; on inert surfaces it persists.

Kode Biotech has designed, made and sold FSL constructs for more than 20 years, with more than 100 in the catalogue and worldwide distribution through GlycoNZ and Merck MilliporeSigma. The same platform underpins Kode Immunoeducers, the group's investigational cancer immunotherapies.

What are FSL (Function-Spacer-Lipid) constructs?

FSL constructs are synthetic molecules that attach almost any small molecule to almost any surface, without a chemical reaction and without genetic change. Each has three parts: a functional head, a spacer and a lipid tail. They are the molecules that make Kode Technology work.

They are amphipathic, meaning one end likes water and the other does not, and they are self-assembling. Added to a cell, virus or surface in solution, the lipid tail buries itself in the membrane and the functional head is left presented on the outside.

More than 100 FSL constructs are catalogued, carrying heads as varied as sugars, peptides, fluorescent labels, biotin and DNA. Kode Biotech also makes constructs to order.

What do the function, spacer and lipid parts do?

The three parts of an FSL construct each do one job. The functional head is the molecule being presented — a glycan, peptide, label or other small molecule. The spacer links it to the lipid and holds it out from the surface. The lipid tail anchors the whole construct into the membrane.

The spacer matters more than it sounds. It keeps the functional head far enough from the surface to be recognised, and its design governs how the construct behaves: its solubility in water, how densely it packs, and whether it can present more than one head at a time.

Changing the head while keeping the spacer and lipid is what lets one platform serve diagnostics, research and therapeutics alike.

How do FSL constructs modify cell and virus surfaces?

FSL constructs modify a surface by inserting into or attaching themselves onto it. Cells or viruses are put in contact with a solution of the construct; the water-hating lipid tail buries itself in the membrane and the functional head is left displayed on the outside. It takes minutes, needs no specialist equipment, and uses no chemical reaction or genetic change.

Because the construct is dispersible in water, no solvent is needed. In the published method the modification does not affect the cell's viability or normal function, and labelled viruses keep their infectivity.

A cell modified this way is called a kodecyte, and a virus a kodevirion. The same approach works on inert surfaces such as plastic, glass, metal and paper.

How stable are FSL constructs?

Two different things are stable here, and it helps to separate them. Simple glycan FSL constructs have a high level of shelf stability: they can be shipped and kept for several months at room temperature, with freezer storage recommended for the long term. Most simple glycan FSL constructs are stable for more than 10 years when stored appropriately. Constructs with complex sugars, peptides or other components may be less stable, and their stability is determined experimentally. The modification they make to a living cell is deliberately temporary, lasting days as the cell's membrane renews itself.

That temporariness is a design feature, not a limitation: it is what allows a cell to be given a new function for an experiment, a control or a treatment, and then return to normal.

On inert surfaces, where there is no membrane turnover, the modification persists. Kode Biotech has designed, made and sold FSL constructs for more than 20 years.

What are kodecytes and kodevirions used for?

A kodecyte is a cell modified with FSL constructs, and a kodevirion is a virus modified the same way. They are used in research, diagnostics, quality assurance and teaching, wherever a cell or virus needs to carry a marker it would not naturally have.

In blood banking, kodecytes serve as quality controls and antibody screening cells, and as serologic mimics of rare blood types that would otherwise be hard to obtain. Products built on them have been on the market since 2005.

In research they are used for fluorescent labelling, cell tracking and virological work. Kodecyte.org is the academic resource for both.

What are the key scientific papers on Kode Technology?

The key publications are highlighted in red in the Science and Publications section.

FAQ: Buying and custom FSL constructs

Can Kode Biotech design custom FSL constructs?

Yes. Essentially any small molecule can be built into an FSL construct, and custom design is a standard part of what Kode Biotech does. If you can name the molecule you want presented on a surface, Kode Biotech can usually make a construct that presents it.

Custom work starts from the same three-part architecture as the catalogue constructs: your molecule becomes the functional head, and Kode Biotech selects the spacer and lipid to suit how it needs to behave — how soluble it must be, how densely it should pack, and what it has to attach to.

More than 100 constructs are already catalogued, so the starting point may already exist. Use the custom FSL enquiry form to describe what you need.

Where can I buy FSL constructs?

FSL constructs are sold by GlycoNZ (glyconz.com) for research and diagnostics, and by Merck MilliporeSigma for research.

The catalogue runs to more than 100 FSL constructs, covering sugars, peptides, labels, biotin and more, alongside GlycoNZ's wider range of glycoconjugates. Pricing and specifications are on the GlycoNZ site.

If what you need is not catalogued, Kode Biotech makes constructs to order: see the custom FSL enquiry form. Technical data on individual constructs is in the Technical Manual, which is free to download.

FAQ: Kode Immunoeducers (KIEs)

What is a Kode Immunoeducer (KIE)?

A Kode Immunoeducer is a membrane-inserting, antibody-recruiting, complement-activating construct with adjuvant-like activity, designed to use the patient's own tumour as the antigen source for in situ vaccination. It is an FSL construct built for a therapeutic job rather than a diagnostic one.

The idea is to inject the construct into a tumour, where it inserts into the tumour cells' membranes and displays a marker the immune system already has antibodies against. That is designed to flag the tumour as foreign and set an immune response going against it.

The KIE supplies the immune-initiating signal; the patient's tumour supplies the antigens. AGI-134, K5K and Kv9 are Kode Immunoeducers. All KIE programmes are investigational.

How is a KIE different from a personalised cancer vaccine?

A Kode Immunoeducer differs from a personalised cancer vaccine in where the antigens come from. A personalised vaccine requires a patient's tumour antigens to be identified, then manufactured into a product for that one patient. A KIE skips both steps.

With a KIE the tumour itself provides the antigens, and they need not be identified in advance. The construct is the same for every patient; what differs is the tumour it is injected into. That is what 'autologous' means here — the antigens are the patient's own.

The practical consequence is manufacturing: one shelf-stable product made in batches, rather than a bespoke product made per patient. KIE programmes remain investigational.

What does “in situ autologous cancer vaccine” mean?

It means the vaccine effect is intended to happen inside the patient's own tumour, using the patient's own tumour as the source of antigens. 'In situ' means in place, in the tumour itself. 'Autologous' means from the same person.

A conventional vaccine delivers an antigen in a vial. An in situ autologous cancer vaccine delivers no antigen at all: it delivers a signal into the tumour and lets the tumour supply the antigens, which are already there and already specific to that patient.

It is the design intent behind every Kode Immunoeducer, and the reason a single product can in principle address many tumour types. The approach is investigational.

What role do pre-existing antibodies and complement play?

They are the immune machinery a Kode Immunoeducer is designed to borrow. Almost everyone already carries large amounts of antibody against certain sugars they never make themselves — α-Gal and rhamnose among them. A KIE displays one of those markers on the tumour.

The marker is intended to recruit those pre-existing antibodies to the tumour and activate complement, part of the immune system that can damage marked cells directly and coat them for collection.

That is designed to promote local tumour injury, inflammatory signalling, and uptake of tumour material by antigen-presenting cells, which in turn may present the tumour's own antigens to T cells. No immunisation is needed beforehand: the antibodies are already there.

What are AGI-134, K5K and Kv9, and what stage is each at?

They are the three Kode Immunoeducer programmes, at three different stages, run by three different companies. All are investigational: none is approved by any medicines regulator.

AGI-134, developed by Kode Agalimmune, is a Gen 2 KIE presenting α-Gal. It has completed a Phase 1/2a safety and dose-finding study in 38 patients with late-stage cancer. The study met its safety endpoint, with no dose-limiting toxicity and the maximum tolerated dose not reached. Stable disease was seen in 11 of the 38 patients, 7 of whom had already failed checkpoint-inhibitor immunotherapy. Side effects were mostly mild to moderate and short-lived, most commonly tiredness and pain at the injection site.

K5K, developed by KodeRx for human cancer, and Kv9, developed by Kode Veterinary Sciences for veterinary cancer, are Gen 3 KIE molecules, identical by structure, presenting rhamnose. K5K is in preparation for first-in-human study. Kv9 is in experimental veterinary clinical trials, and neither is approved for use.

What is the difference between Kv9 and K5K?

Kv9 and K5K are identical molecules by structure. Their formulation and the regulatory pathways for their clinical products may be different: Kv9 is being developed by Kode Veterinary Sciences for veterinary use, and K5K by KodeRx for human use.

Their mode of action is expected to be the same in dogs as in people. Both are investigational: neither is approved by any regulator.

Why are there generations of KIEs?

Each generation refines the design, and the differences are in the marker presented and how the immune system is engaged. The generations are not versions of one product: they are distinct constructs for distinct programmes.

The Gen 2 KIE, AGI-134, presents α-Gal and relies on the anti-Gal antibodies a patient already carries to recruit complement by the classical route. It is the generation with human clinical experience behind it.

The Gen 3 KIEs, K5K and Kv9, present rhamnose instead, on a redesigned construct intended to improve on the Gen 2 KIEs. Details will be published in due course. All generations remain investigational.

Why is a KIE tested in dogs?

Because pet dogs develop cancer naturally, with an intact immune system, in a way laboratory models cannot reproduce. A dog with a spontaneous tumour shows how a Kode Immunoeducer behaves in a real tumour, in a real immune system, in an animal living a normal life.

This is established practice, not a Kode Biotech invention: the United States National Cancer Institute runs a Comparative Oncology Program that studies pet dogs with cancer for exactly this reason, and treats the findings as informative for human disease.

It also serves dogs directly. Canine cancer is common and poorly served, and Kode Veterinary Sciences is developing Kv9 as a veterinary treatment in its own right. The canine work is translational evidence: it cannot establish what will happen in people, and both programmes are investigational.

FAQ: Kode Biotech and the Kode Group

Who founded Kode Biotech, and where is it based?

Kode Biotech was founded by Stephen Henry in New Zealand in 1996, originally as Kiwi Ingenuity Limited, and took the name Kode Biotech Limited in 2006. It has been based in Auckland throughout.

Stephen Henry and Nicolai Bovin invented Kode Technology. Stephen Henry remains the company's chief executive. He is Professor Emeritus at Auckland University of Technology and a Fellow of the Royal Society Te Apārangi, which awarded him the Pickering Medal in 2017 for the technology's development.

The company began with natural glycolipids used to modify red cells for blood bank quality control, and made its first synthetic FSL construct in 2003. The full history is on our story.

Which companies are in the Kode Group, and how do they relate?

Kode Biotech Limited owns the Kode Technology platform and its intellectual property, and licenses it to companies set up to take each application to market. There are two kinds.

The spin-out companies develop Kode Immunoeducers: Kode Agalimmune for AGI-134, KodeRx for K5K in human cancer, and Kode Veterinary Sciences for Kv9 in veterinary cancer. The supply subsidiaries sell constructs: GlycoNZ for research and diagnostic FSL constructs and glycoconjugates, and Kode Biotech Materials for large-scale, quality-assured direct supply to pharmaceutical companies.

The structure and ownership are set out on the Kode Group page.

What is Equitable Oncology's relationship with Kode?

Equitable Oncology is an independently governed New Zealand registered charity (CC64930) working to improve equitable access to cancer treatment. It is not a Kode Group company and has its own Board, Constitution and charitable purpose.

The first programme selected to progress through the Equitable Oncology Model is K5K, an investigational Gen 3 KIE developed by Kode Biotech. KodeRx is the commercialisation company responsible for advancing K5K through clinical development and towards commercialisation.

Equitable Oncology works collaboratively with KodeRx, coordinating partnerships and bringing together expertise, capabilities and resources to support K5K's progression. Building on the affordability and accessibility principles embedded in K5K's development, the Equitable Oncology Model aims to minimise costs ultimately passed on to patients and improve access to cancer treatment.

Kode Biotech holds a 26% shareholding in Equitable Oncology, providing a constitutional mission lock that supports long-term alignment with Equitable Oncology's charitable purpose. As an independently governed charitable company, Equitable Oncology does not distribute dividends, and Kode Biotech receives no financial distributions from its shareholding.

Equitable Oncology, in turn, holds 26% non-dilutable interests in both KodeRx and Kode Agalimmune. These strategic shareholdings provide a mechanism through which potential future commercial returns can support Equitable Oncology's charitable purpose and be reinvested in programmes and initiatives that improve access to cancer treatment.

Equitable Oncology and the Kode companies have distinct but complementary roles, with independent governance and decision-making. More at equitableoncology.com.

Does Kode Biotech control Equitable Oncology?

No. Equitable Oncology is an independently governed New Zealand registered charity (CC64930), with its own Board, Constitution and charitable purpose. Kode Biotech's 26% shareholding provides a constitutional mission lock, supporting long-term alignment with Equitable Oncology's charitable purpose without giving Kode Biotech control over its activities.

Equitable Oncology's Board is responsible for its strategic direction and decision-making, including determining which programmes and partnerships to support and how resources are allocated in accordance with its charitable purpose.

This independence ensures that Equitable Oncology's decisions are guided by its charitable purpose, rather than the commercial interests of any individual company or partner.

Who owns the Kode Technology IP?

Kode Biotech Limited owns Kode Technology and its intellectual property, and licenses it to the companies in the group. Ownership has never been divided: the platform, the patents and the know-how sit with the parent company.

That matters for anyone considering a partnership. A licence for one application does not fragment the platform, and a programme company's commercial arrangements do not affect the underlying technology.

The first patent was filed in 2004, for synthetic membrane anchors, and the estate has grown with the platform since. Kode Biotech's intellectual property is managed by Dr Stephen Parker of Intellectual Property and Patent Consultants, a co-inventor on Kode Technology patents.

How can my organisation partner with Kode Biotech?

Where to start depends on what you want to do, because the group routes partnerships by application.

For licensing and commercial partnerships on Kode Immunoeducers in human cancer, approach KodeRx for K5K or Kode Agalimmune for AGI-134. For Kode Immunoeducers in veterinary cancer, approach Kode Veterinary Sciences. For anything to do with the platform itself (licensing Kode Technology for a new application, a custom FSL construct, or a research collaboration), approach Kode Biotech.

Equitable Oncology, an independently governed charity, coordinates the clinical, scientific and philanthropic partnerships that advance K5K and AGI-134.

Kode Biotech licenses the platform rather than developing every application itself, so a licence for a field nobody is working in is a normal conversation. Contact Kode Biotech to start one.

Where can I read the science behind Kode Technology?

The science is published and free to read. The fullest single source is the Kode Technology Illustrated Technical Manual, a 2023 reference covering the platform, the construct architecture and the data behind it, published under a Creative Commons licence.

Stephen Henry's DSc thesis covers the technology's development across three decades. Both are held by the University of Auckland and the National Library of New Zealand.

Peer-reviewed papers, with DOIs, are listed on Science and Publications. The downloads are on Downloads, and kodecyte.org is the academic resource for the technology.

Still have a question? contact Kode Biotech

Tell us what you need and we'll route it to the right team.